Background: The T-cell-mediated contact hypersensitivity reaction (CHR) is thought to be involved in the pathogenesis of clinical cutaneous disorders including atopic dermatitis. A novel diaminouracil derivative, CX-659S, has been reported to have an inhibitory activity against picryl chloride (PC)-induced CHR when administered either orally or percutaneously. The inhibitory effect of topical CX-659S was assessed in three CHR models in the present study. In addition, to elucidate the mechanism of action of this compound, we examined the effect of CX-659S on the expression of messenger RNAs for proinflammatory cytokines after elicitation in PC models. Methods: For the in vivo evaluation of the efficacy of CX-659S, we used PC- or oxazolone-induced CHR in mice and 2,4-dinitrochlorobenzene (DNCB)-induced CHR in guinea pigs. CX-659S was topically applied immediately after the hapten challenge in each model. To assess the effect on gene expression of cytokines, we used the reverse transcriptase-polymerase chain reaction (RT-PCR), a semiquantitative technique with specific primers. Results: Topical CX-659S dose-dependently inhibited ear swelling at 24 h after the challenge in the two mouse models. This inhibitory effect was histologically confirmed in the PC model. Topically applied CX-659S also inhibited erythema and edema formation 24 h after challenge in the guinea pig model. CX-659S inhibited the expression of mRNA for proinflammatory cytokines IL-1β and TNF-α in vivo. Conclusions: Topically applied CX-659S showed significant inhibitory activities against CHR models both in mice and in guinea pigs. Inhibition profiles of CX-659S toward mRNA expression for proinflammatory cytokines corroborated these findings. CX-659S thus could be a useful therapeutic agent for allergic cutaneous disorders such as allergic contact dermatitis and atopic dermatitis.

1.
Landsteiner K, Chase MW: Experiments on transfer of cutaneous sensitivity to simple chemical compounds. Proc Soc Exp Biol Med 1942;49:688–690.
2.
Becker D, Knop J: Mechanism in allergic contact dermatitis. Exp Dermatol 1993;2:63–69.
3.
Grabbe S, Schwarz T: Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Am J Contact Dermat 1996;7:238–248.
4.
Kalish RS: Recent developments in the pathogenesis of allergic contact dermatitis. Arch Dermatol 1991;127:1558–1563.
5.
Kondo S, Sauder DN: Epidermal cytokines in allergic contact dermatitis. J Am Acad Dermatol 1995;33:786–800.
6.
Enk AH, Angeloni VL, Udey MC, Katz SI: An essential role for Langerhans cell-derived IL-1β in the initiation of primary immune responses in skin. J Immunol 1993;150:3698–3704.
7.
Piguet PF, Grau GE, Hauser C, Vassalli P: Tumor necrosis factor is a critical mediator in hapten-induced irritant and contact hypersensitivity reactions. J Exp Med 1991;173:673–679.
8.
Herz U, Bunikowski R, Renz H: Role of T cells in atopic dermatitis: New aspects on the dynamics of cytokine production and the contribution of bacterial superantigens. Int Arch Allergy Immunol 1998;115:179–190.
9.
Tobe M, Isobe Y, Goto Y, Obara F, Tsuchiya M, Matsui J, Hirota K, Hayashi H: Synthesis and biological evaluation of CX-659S and its related compounds for their inhibitory effects on the delayed-type hypersensitivity reaction. Bioorg Med Chem 2000;8:2037–2047.
10.
Enk AH, Katz SI: Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci USA 1992;89:1398–1402.
11.
Bach JF: The mode of action of immunosuppressive agents; in Frontiers of Biology. Amsterdam, North-Holland, 1975, vol 41.
12.
Nakagawa S, Oka D, Jinno Y, Takei Y, Bang D, Ueki H: Topical application of cyclosporine on guinea pig allergic contact dermatitis. Arch Dermatol 1988;124:907–910.
13.
Biren CA, Barr RJ, Ganderup GS, Lemus LL, McCullough: Topical cyclosporine: Effects on allergic contact dermatitis in guinea pigs. Contact dermatitis 1989;20:10–16.
14.
Lauerma AI, Stein BD, Homey B, Lee CH, Bloom E, Maibach HI: Topical FK-506: suppression of allergic and irritant contact dermatitis in the guinea pig. Arch Dermatol Res 1994;286:337–340.
15.
Wojnar RJ, Brittain RJ: Substituted 9-benzyladenines: Inhibitors of inflammation associated with the delayed hypersensitivity skin reaction. Agents Actions 1975;5/2:152–160.
16.
Kondo S, Pastore S, Fujisawa H, Shivji GM, McKenzie RC, Dinarello CA, Sauder DN: Interleukin-1 receptor antagonist suppresses contact hypersensitivity. J Invest Dermatol 1995;105:334–338.
17.
Epstein SP, Baer RL, Thorbecke GJ, Belsito DV: Immunosuppressive effects of transforming growth factor β: Inhibition of the induction of Ia antigen on Langerhans cells by cytokines and of the contact hypersensitivity response. J Invest Dermatol 1991;96:832–837.
18.
Asahina A, Hosoi J, Beissert S, Stratigos A, Granstein RD: Inhibition of the induction of delayed-type and contact hypersensitivity by calcitonin gene-related peptide. J Immunol 1995;154:3056–3061.
19.
Wilmer WA, Tan LC, Dickerson JA, Danne M, Rovin BH: Interleukin-1β induction of mitogen-activated protein kinases in human mesangial cells. Role of oxidation. J Biol Chem 1997;272:10877–10881.
20.
Goossens V, De Vos K, Vercammen D, Steemans M, Vancompernolle K, Fiers W, Vandenabeele P, Grooten J: Redox regulation of TNF signaling. Biofactors 1999;10:145–156.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.